Last updated: November 11, 2026
Flortaucipir F-18, marketed by Eli Lilly as Tauvid, is the first FDA-approved tau PET imaging agent for estimating the density and distribution of aggregated neurofibrillary tau tangles in adults undergoing evaluation for Alzheimer’s disease. Its commercial opportunity is constrained by PET infrastructure, radiopharmaceutical manufacturing, specialist interpretation, reimbursement limits, and the availability of established amyloid PET agents. Lilly does not separately disclose Tauvid revenue, so its financial trajectory must be inferred from regulatory adoption, imaging volumes, Alzheimer’s diagnostics spending, and the company’s broader neuroscience portfolio.
What is flortaucipir F-18 and what is Tauvid used for?
Tauvid is an intravenous radioactive diagnostic agent containing flortaucipir F-18. The fluorine-18-labeled tracer binds to aggregated tau pathology and is visualized with positron emission tomography.
The FDA approved Tauvid on May 28, 2020, under NDA 212123. The approved indication is limited to brain imaging in adults being evaluated for Alzheimer’s disease. The label states that Tauvid is an adjunct to other diagnostic evaluations and that a positive or negative Tauvid scan does not independently establish or exclude Alzheimer’s disease [1].
Tauvid differs from amyloid PET agents because it targets tau pathology rather than beta-amyloid plaques. The distinction matters commercially:
| Product |
Active tracer |
Target |
Sponsor |
FDA approval |
| Tauvid |
Flortaucipir F-18 |
Aggregated tau |
Eli Lilly |
May 28, 2020 |
| Amyvid |
Florbetapir F-18 |
Beta-amyloid plaques |
Eli Lilly |
April 6, 2012 |
| Vizamyl |
Flutemetamol F-18 |
Beta-amyloid plaques |
GE HealthCare |
October 25, 2013 |
| Neuraceq |
Florbetaben F-18 |
Beta-amyloid plaques |
Life Molecular Imaging |
March 20, 2014 |
Tauvid is the only FDA-approved tau PET tracer listed in the FDA’s approved drug database as of the latest public approval information reviewed [2].
How large is the market for flortaucipir F-18?
The addressable market is the U.S. Alzheimer’s disease diagnostic imaging segment, not the entire dementia market.
The commercial market is limited by five factors:
- Alzheimer’s disease evaluation remains primarily clinical.
- Tau PET requires access to PET or PET/CT equipment.
- Radiopharmaceuticals must be manufactured and delivered within the isotope’s short half-life.
- Nuclear medicine physicians or trained readers must interpret the scan.
- Payer coverage is narrower than the potential clinical population.
Tauvid’s potential users include memory clinics, academic medical centers, neurology practices linked to imaging networks, clinical trial sites, and centers evaluating patients for disease-modifying Alzheimer’s therapies.
The launch opportunity expanded after anti-amyloid therapies increased demand for biomarker confirmation. However, anti-amyloid treatment selection generally relies on amyloid confirmation, not tau PET. Tauvid therefore benefits indirectly from greater biomarker adoption but does not have the same direct treatment-selection role as amyloid PET.
How does Tauvid compare with amyloid PET agents?
Amyloid PET has an earlier commercial position, broader clinical familiarity, and more established reimbursement experience. Tauvid provides information on a later-stage pathological process and may improve disease staging, prognosis, trial enrichment, and treatment-response assessment.
| Commercial factor |
Tauvid |
Amyloid PET agents |
| Pathology measured |
Tau neurofibrillary tangles |
Beta-amyloid plaques |
| Primary clinical role |
Disease characterization and staging |
Alzheimer’s pathology confirmation |
| Approved product age |
Since 2020 |
Since 2012 |
| Treatment-selection relevance |
Indirect |
More direct for anti-amyloid therapy eligibility |
| Competition |
Limited approved competition |
Multiple approved tracers |
| Infrastructure |
PET imaging and radiopharmacy |
PET imaging and radiopharmacy |
| Reimbursement maturity |
Developing |
More established but still constrained |
Tauvid’s differentiation is technically strong, but its use case is narrower than the use case for amyloid imaging.
What is the financial trajectory of Tauvid?
Lilly does not report Tauvid revenue as a separate line item in its annual reports. Tauvid is grouped within Lilly’s broader product portfolio, and the company has not publicly disclosed product-specific sales, unit volumes, operating margins, or profitability for the tracer [3].
That reporting structure prevents a precise revenue estimate. The financial trajectory can be characterized as follows:
| Period |
Financial and commercial condition |
| 2020 |
FDA approval and initial commercialization during the COVID-19 disruption |
| 2021-2022 |
Early adoption constrained by limited imaging capacity and uneven diagnostic utilization |
| 2023 |
Greater Alzheimer’s biomarker awareness and increased interest in disease staging |
| 2024 onward |
Potential demand growth from Alzheimer’s diagnostics, clinical trials, and treatment-monitoring research |
| Long term |
Revenue remains dependent on reimbursement, PET capacity, and whether tau imaging becomes routine clinical practice |
Tauvid is unlikely to be a material standalone driver of Lilly’s consolidated revenue compared with major therapeutic products such as Mounjaro, Zepbound, Verzenio, Taltz, and Trulicity. Its strategic value is greater than its likely near-term revenue contribution. The product gives Lilly a position in Alzheimer’s biomarker infrastructure and complements the company’s broader neuroscience and diagnostic interests.
What determines Tauvid revenue?
The main revenue drivers are:
- Number of Alzheimer’s evaluations involving PET imaging
- Use of Tauvid in specialty memory centers
- Clinical-trial enrollment and screening
- Payer reimbursement and patient cost sharing
- Availability of local or regional radiopharmacies
- FDA approvals of Alzheimer’s disease-modifying therapies
- Adoption of tau imaging in disease staging and prognosis
- Potential use in longitudinal clinical research
Radiopharmaceutical revenue is also sensitive to production logistics. Flortaucipir F-18 has a short physical half-life of approximately 110 minutes. Manufacturing, quality release, dose preparation, and delivery must be coordinated around the imaging appointment. That limits the practical geographic radius of each production site and raises the importance of distribution partnerships.
When does Tauvid lose regulatory and patent exclusivity?
Tauvid’s FDA approval date was May 28, 2020. FDA regulatory exclusivity and patent exclusivity are separate rights.
The key public milestones are:
| Rights category |
Status |
| FDA approval |
May 28, 2020 |
| NDA |
212123 |
| Regulatory exclusivity |
Any initial statutory exclusivity is tied to the 2020 approval and is not the same as patent protection |
| Orange Book patent listing |
No active patent listing was identified in the public Orange Book data reviewed |
| Patent expiry |
No single publicly verified patent expiry date establishes a current U.S. market barrier |
| Generic or 505(b)(2) entry |
No publicly identified approved competing flortaucipir product |
Tauvid’s commercial protection is therefore less dependent on a conventional long-duration small-molecule patent monopoly than on regulatory know-how, radiopharmacy scale, clinical adoption, physician familiarity, and supply infrastructure.
A conventional generic challenge is also less straightforward than for an oral tablet. A potential competitor would need to demonstrate pharmaceutical equivalence and establish an appropriate FDA pathway for a radioactive diagnostic injection. A 505(b)(2) application or another abbreviated pathway could be more relevant than a conventional ANDA, depending on the proposed product and FDA classification.
What is the Orange Book status of flortaucipir F-18?
The Orange Book identifies approved drug products and, where applicable, related patent and exclusivity information. The public FDA sources reviewed identify Tauvid under NDA 212123, but no active Orange Book patent listing was identified as a current barrier to competition [4].
This does not eliminate other forms of intellectual-property protection. Lilly may hold patents covering tracer synthesis, precursor compounds, radiolabeling processes, imaging methods, formulations, or specific diagnostic uses. Those rights may not be listed in the Orange Book or may have limited relevance to a competing product using a different manufacturing route.
For market analysis, the practical conclusion is that Tauvid does not present the same visible Orange Book patent risk associated with heavily patented chronic therapies.
Are there Paragraph IV challenges to Tauvid?
No publicly identified Paragraph IV litigation or FDA-approved generic challenge has established a current market-entry event for flortaucipir F-18.
Paragraph IV litigation is less likely to follow the standard pattern seen in high-volume oral drugs because:
- Tauvid has a specialized diagnostic indication.
- The product is radioactive and time-sensitive.
- Commercial demand is concentrated in a limited number of imaging centers.
- Manufacturing and distribution require radiopharmaceutical capabilities.
- The economic incentive for an ANDA filer may be smaller.
- A competing developer could pursue a different regulatory route or a non-infringing manufacturing process.
The absence of a public Paragraph IV case does not mean that competition is impossible. It indicates that no known challenger has converted the opportunity into a visible U.S. litigation or approval event.
What patent estate protects Tauvid?
The most relevant potential patent categories are product composition, radiolabeling chemistry, precursors, synthesis, formulations, and diagnostic-use claims.
Product and composition claims
Flortaucipir is a small-molecule imaging agent rather than a biologic. Composition claims may cover the tracer or related chemical structures, but their commercial value depends on claim scope, expiration, prosecution history, and whether an alternative tracer can avoid infringement.
Manufacturing and radiolabeling claims
Manufacturing protection may cover:
- Preparation of the nonradioactive precursor
- Fluorine-18 incorporation
- Purification and formulation
- Automated synthesis systems
- Quality-control methods
- Dose preparation and handling
These rights can create operational barriers even when they do not prevent a competitor from developing a different process.
Method-of-use claims
Potential method claims may cover imaging tau pathology, detecting Alzheimer’s disease, distinguishing disease stages, or selecting patients for research studies. Method-of-use claims are difficult to enforce against routine clinical use when the product label, physician conduct, and reimbursement records do not clearly establish the patented method.
Formulation patents
Tauvid is administered as a sterile intravenous injection. Formulation protection is likely to be narrower than for a complex depot or oral delivery product. The commercially important formulation issues are radiochemical purity, stability, sterility, specific activity, and shelf-life rather than differentiated patient-delivery technology.
How strong is the Tauvid patent estate?
Tauvid’s patent estate should be viewed as moderate in commercial leverage and weaker than the patent estates surrounding many chronic specialty drugs.
Its strengths are:
- Specialized tracer chemistry
- Regulatory approval for a first-in-class tau imaging indication
- Manufacturing complexity
- Limited number of qualified radiopharmacy suppliers
- Clinical data and reader-training infrastructure
- Potential know-how around quality control and dose distribution
Its weaknesses are:
- No dependence on a chronic treatment market
- Limited public evidence of an active Orange Book patent barrier
- Potential availability of non-infringing tau tracers
- Narrow clinical use case
- Short product half-life and localized distribution economics
- Limited ability to prevent competing diagnostic technologies
The largest competitive threat is not necessarily a flortaucipir copy. It is a next-generation tau tracer with better binding characteristics, lower background signal, improved staging performance, broader distribution, or better workflow economics.
Which companies are challenging Tauvid?
No company has publicly established a direct commercial challenge through an approved competing tau PET product in the United States.
The competitive field includes developers of investigational tau PET agents such as:
- Life Molecular Imaging, associated with PI-2620 development activity
- Roche and affiliated research groups, associated with tau PET tracer programs including RO-948
- Academic and biotechnology groups developing MK-6240 and related tau tracers
- University-linked programs pursuing tau imaging agents for Alzheimer’s disease and other tauopathies
These programs may compete with Tauvid in clinical trials and future diagnostic use, even if they do not infringe Lilly’s flortaucipir claims. The most important competitive variable is clinical utility, not merely FDA approval sequence.
What reimbursement risks affect Tauvid?
Reimbursement is the central commercial risk.
Medicare coverage for PET imaging in dementia has historically developed through national coverage decisions, coverage-with-evidence-development policies, and local contractor determinations. Coverage for amyloid PET and coverage for tau PET are not interchangeable. The existence of an FDA-approved tracer does not guarantee broad payment for every intended clinical use [5].
Commercial insurers may impose prior authorization, medical-necessity review, or site-of-care restrictions. Patients may also face substantial cost exposure when scans are performed outside covered indications.
Tauvid adoption will improve if:
- Tau PET changes diagnosis or management;
- professional societies incorporate tau imaging into clinical pathways;
- evidence links tau burden to treatment response or prognosis;
- payers establish consistent coverage;
- PET capacity expands beyond academic centers.
What generic launch scenarios exist for Tauvid?
Three scenarios are commercially plausible.
Scenario 1: No direct generic entry
Lilly retains the market through brand recognition, supply relationships, manufacturing know-how, and the limited size of the opportunity. This is the most conservative near-term scenario.
Scenario 2: A 505(b)(2) or equivalent competitor
A competitor launches a flortaucipir-based product using a differentiated manufacturing process, separate supply network, or alternative formulation. Price competition would likely be regional before becoming national because of isotope logistics.
Scenario 3: Replacement by a next-generation tau tracer
A competing tau tracer demonstrates better diagnostic performance or more useful disease staging. In that case, Tauvid could lose share without a direct patent challenge. This is the most important long-term competitive risk.
What litigation and licensing activity affects Tauvid?
No major public patent litigation or settlement agreement involving Tauvid was identified in the sources reviewed. Lilly’s ownership of Tauvid follows its acquisition of Avid Radiopharmaceuticals, a company Lilly acquired in 2010 [6].
Avid’s broader imaging portfolio included amyloid and tau diagnostic programs. The acquisition gave Lilly control over development capabilities, clinical data, regulatory assets, and radiopharmaceutical relationships. That transaction remains commercially relevant because it positioned Lilly across both amyloid and tau imaging rather than relying on a single diagnostic product.
No publicly disclosed licensing deal has been identified as a material current driver of Tauvid revenue.
How does Tauvid compare with Lilly’s Amyvid?
Tauvid and Amyvid are complementary but occupy different positions.
| Factor |
Tauvid |
Amyvid |
| FDA approval |
2020 |
2012 |
| Target |
Tau |
Amyloid |
| Clinical maturity |
Newer |
More established |
| Role in anti-amyloid treatment pathway |
Supportive or exploratory |
More directly relevant |
| Patent and competition profile |
Specialized, limited direct competition |
Older product with multiple amyloid PET alternatives |
| Revenue transparency |
Not separately disclosed |
Not separately disclosed |
| Strategic value |
Tau biomarker leadership |
Amyloid biomarker infrastructure |
Amyvid has a broader historical clinical footprint, but Tauvid may benefit from greater interest in disease staging and progression. Lilly’s combined position can support cross-selling to imaging networks, although physician demand is determined by clinical need and payer policy rather than portfolio ownership alone.
Key Takeaways
- Tauvid is the FDA-approved flortaucipir F-18 tau PET tracer marketed by Eli Lilly.
- FDA approval occurred on May 28, 2020, under NDA 212123.
- Lilly does not separately report Tauvid revenue, preventing a verified product-level financial estimate.
- Tauvid’s commercial market is limited by PET capacity, radiopharmacy logistics, reimbursement, and specialist interpretation.
- The product benefits from broader Alzheimer’s biomarker adoption but is less directly connected to treatment selection than amyloid PET.
- No active Orange Book patent listing or public Paragraph IV challenge was identified in the sources reviewed.
- Manufacturing know-how, radiopharmaceutical distribution, clinical data, and physician familiarity may provide more practical protection than a visible patent barrier.
- The main long-term threat is a superior next-generation tau tracer, not necessarily a conventional generic copy.
- Tauvid is strategically relevant to Lilly’s neuroscience and diagnostic portfolio but is unlikely to be a major standalone revenue contributor.
FAQs
Is flortaucipir F-18 the same as Tauvid?
Yes. Tauvid is Eli Lilly’s brand name for flortaucipir F-18 injection.
Can Tauvid diagnose Alzheimer’s disease by itself?
No. Tauvid imaging must be interpreted with other clinical, cognitive, laboratory, and imaging information. The FDA label does not authorize Tauvid as a standalone diagnostic test [1].
Is Tauvid used to determine eligibility for Leqembi or Kisunla?
Anti-amyloid therapies generally require evidence of amyloid pathology. Tauvid measures tau pathology and is not the primary biomarker used to establish amyloid eligibility.
Does Tauvid have biosimilar competition?
No. Tauvid is a radiolabeled small-molecule diagnostic, not a biologic. Biosimilar regulation does not apply.
What is the largest commercial risk to Tauvid?
The largest risk is limited reimbursement combined with competition from next-generation tau PET tracers that demonstrate better clinical utility or workflow economics.
References
- U.S. Food and Drug Administration. (2020). Tauvid (flortaucipir F 18 injection) prescribing information.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Tauvid NDA 212123.
- Eli Lilly and Company. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Centers for Medicare & Medicaid Services. (2023). National coverage determination 220.6: Positron emission tomography.
- Eli Lilly and Company. (2010). Lilly to acquire Avid Radiopharmaceuticals. Eli Lilly investor and corporate communications materials.
